Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216572 | 0.90 | PARP1 (0.39) | PARP1POLBL3MBTL1 | |
| SCHEMBL7215155 | 0.79 | PARP1 (0.38) | PARP1 | |
| SCHEMBL7214410 | 0.72 | PARP1 (0.54) | PARP1 | |
| SCHEMBL27772941 | 0.59 | POLB (0.35) | PARP1POLBL3MBTL1ADRB2ADRB1 | |
| SCHEMBL13254982 | 0.59 | SIRT3 (0.42) | POLBL3MBTL1ADRB2ADRB1ADRB3 | |
| SCHEMBL13254974 | 0.59 | SIRT3 (0.42) | POLBL3MBTL1ADRB2ADRB1ADRB3 | |
| SCHEMBL18964182 | 0.59 | KDM4E (0.50) | POLBADRB2ADRB1ADRB3ADRA1D | |
| SCHEMBL13254984 | 0.59 | SIRT3 (0.42) | POLBL3MBTL1ADRB2ADRB1ADRB3 | |
| SCHEMBL28813806 | 0.58 | L3MBTL1 (0.37) | PARP1POLBL3MBTL1ADRB2ADRB1 | |
| SCHEMBL6369200 | 0.58 | PARP1 (0.44) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576766-B1 | Competitive binding of phosphotyrosine-containing protein; veterinary medicine | ARIAD PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-6573295-B2 | Treating proliferative diseases, cancer, restenosis, osteoporosis, inflammation, aIlergies, or cardiovascular disease. | ARIAD PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | SHAKESPEARE WILLIAM C (US) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062031-A1 | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof | ACP1, SRC, PPM1G | PARP1 2454/4885POLB 4412/4885L3MBTL1 3244/4885 |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | PARP1 3059/4885POLB 4445/4885L3MBTL1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.